Spin labelled arabinogalactan as MRI contrast agent

Area of Science:

• Biomedical Imaging
• Materials Science
• Hepatology

Background:

• Developing novel MRI contrast agents is crucial for enhanced diagnostic imaging.
• Targeted delivery systems can improve contrast agent specificity and efficacy.
• Arabinogalactan's recognition by hepatocyte asialoglycoprotein receptors offers a targeting strategy.

Purpose of the Study:

• To synthesize and evaluate Spin Labelled ArabinoGalactan (SLAG) as an MRI contrast agent.
• To assess SLAG's targeting capability to hepatocytes via the asialoglycoprotein receptor.
• To compare the liver contrast enhancement of SLAG with its non-targeted precursor, PCA.

Main Methods:

• Synthesis of arabinogalactan/pyrrolidinoxyl radicals (PCA) covalent adduct (SLAG).
• Electron paramagnetic resonance (EPR) spectroscopy and molecular dynamics for relaxivity studies.
• In vitro binding assays with isolated hepatocytes.
• In vivo MRI studies on mice using spin-echo T1 weighted sequences.

Main Results:

• SLAG exhibited higher R1 relaxivity in water compared to PCA, attributed to radical immobilization.
• SLAG demonstrated specific binding to the asialoglycoprotein receptor on hepatocytes.
• In vivo MRI showed a 40% signal enhancement in the liver for SLAG versus 13% for PCA at 5 minutes post-injection.
• Significant signal increase was also observed in the renal cortex, with contrast lasting up to 3 hours.

Conclusions:

• SLAG functions as an effective MRI contrast agent with enhanced liver targeting.
• The study confirms SLAG's ability to bind to the asialoglycoprotein receptor.
• Observed non-selective biodistribution may be due to high concentrations saturating the receptor, warranting further investigation.